Table 1.
Clinical–pathological characteristics of all melanoma patients enrolled in the study
| Clinical–pathological features of 1023 patients treated for melanoma | N |
|---|---|
| Gender | |
| Male | 487 (47.6%) |
| Female | 536 (52.4%) |
| Age (years) | |
| Median [range] | 54 [13–96] |
| TNM stage (2009 AJCC melanoma staging system) | |
| Stage 0 | 181 (17.7%) |
| Stage I | 549 (53.7%) |
| Stage II | 183 (18.0%) |
| Stage III | 40 (4.0%) |
| Stage IV | 23 (2.2%) |
| Unknown/not applicable | 45 (4.6%) |
| Pathological TNM stage (pT) | |
| pTis | 179 (17.5%) |
| pT1 | 429 (41.9%) |
| pT2 | 166 (16.2%) |
| pT3 | 113 (11.0%) |
| pT4 | 82 (8.0%) |
| Unknown/not applicable | 54 (5.3%) |
| Histological ulceration | |
| Present | 132 (12.9%) |
| Absent | 675 (66.0%) |
| Unknown/not applicable | 216 (21.1%) |
| Tumor-infiltrating lymphocytes | |
| Absent | 645 (63.0%) |
| Non-brisk | 257 (25.1%) |
| Brisk | 74 (7.2%) |
| Unknown/not applicable | 47 (4.6%) |
| Disease-free survival (months) | |
| Median [range] | 28.7 [28.7 to N.R.] |
| Overall survival | |
| Median | N.R. |
Values in table are presented as the number (of patients) with either the range (in square brackets) or the percentage (in parenthesis)
AJCC 2009 American Joint Committee on Cancer, N.R. not reached